BeyondSpring reports Q2 EPS (10c) vs (4c) last year

“At the heart of BeyondSpring’s (BYSI) pipeline is Plinabulin, a first-in-class agent potentially redefining cancer treatment by harnessing the body’s own immune system,” said Dr. Lan Huang, Co-Founder, Chair, and CEO. “Plinabulin’s ability to mature dendritic cells in human studies, bridges innate and adaptive immunity, offering potentially new hope to the 60% of NSCLC patients whose disease progresses after checkpoint inhibitor therapy. In our global Phase 3 trial, plinabulin and docetaxel combination compared to standard of care docetaxel alone, delivered durable survival benefits alongside reduced chemotherapy-induced neutropenia – a combination with strong potential to influence standards of care.”